Return to search results.
Complete title: A Phase I/II Study of Lintuzumab-Actinium-225 in Older Patients with Untreated Acute Myeloid Leukemia (AML)
|Research Study Number||2572.00|
|Principal Investigator||Johnnie Orozco, MD, PhD|
Research Study Description
- The goal of the Phase I part of this study is to find the highest tolerable dose of Lintuzumab-Ac225 that can be given with cytarabine to patients with AML.
- The goal of the Phase II part of this study is to learn if Lintuzumab-Ac225 and cytarabine can control AML. The safety of this drug combination will also be studied.
- Lintuzumab-Ac225 is designed to deliver radiation therapy directly inside leukemia cells without giving any radiation to the surrounding normal cells
- Cytarabine is designed to insert itself into DNA (genetic material) of cancer cells and stop the DNA from repairing itself.
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Leukemia, Myeloid; Immunotherapy
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.